Rivera-Woll L M, Davis S R
The Jean Hailes Foundation, National Health and Medical Research Council Centre of Clinical Research Excellence, Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia.
Intern Med J. 2004 Mar;34(3):109-14. doi: 10.1111/j.1444-0903.2004.00555.x.
The use of postmenopausal hormone therapy (HT) has recently generated much debate following the results of various large randomised controlled trials. This has challenged physicians to reassess the use of HT in each individual woman within the realm of her symptomatology and risk profile for long-term illnesses. There are several areas of definite benefit or risk and many areas of uncertainty. The results of recent randomised controlled trials pertain to the specific HT regimens used and the characteristics of the study groups, such that the conclusions cannot be extrapolated to the use of HT in general.
绝经后激素疗法（HT）的使用在各种大型随机对照试验得出结果后，近来引发了诸多争论。这促使医生在每位女性的症状表现及长期疾病风险状况范围内，重新评估HT的使用。存在几个明确的获益或风险领域，也有许多不确定的领域。近期随机对照试验的结果与所使用的特定HT方案及研究组的特征相关，因此这些结论不能外推至一般的HT使用情况。
